Esperion Therapeutics Inc
NASDAQ:ESPR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Esperion Therapeutics Inc
Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Revenue Growth: Esperion delivered total Q3 2025 revenue of $87.3 million, up 69% year-over-year, marking its strongest third quarter on record.
Prescription Momentum: U.S. net product revenue rose 31% year-over-year to $40.7 million, with a 9% increase in total retail prescription equivalents from the previous quarter.
Strategic Investments: Short-term expenses for patient access and marketing programs reduced sequential growth, but management expects these to drive future revenue.
Guideline Endorsements: Bempedoic acid received a Class 1 Level A recommendation in European guidelines, with similar U.S. guideline inclusion expected in early 2026.
International Expansion: Royalties from Daiichi Sankyo Europe rose 21% sequentially, and Japan is set for imminent launch after receiving marketing approval and favorable pricing.
Profitability Outlook: Management reaffirmed confidence in achieving ongoing profitability in Q1 2026, excluding milestone payments, and expects gross margins to improve in 2026.
Operating Expense Guidance: Full year 2025 operating expenses are guided at $215–235 million, unchanged from previous guidance.
